TKT and neoplasm: When the anti-tumour activity was compared, the data at low doses of M7 and M8 showed both had anti-tumour activity superior to that of Adv-TK in combination with any dose of GCV, whilst M8 showed the most potent effect of all the mutants (Figure 3A–D).